Cover Image
市場調查報告書

蛋白質、肽口服藥市場

Oral Proteins and Peptides Market (3rd Edition), 2018 - 2030

出版商 ROOTS ANALYSIS 商品編碼 290265
出版日期 內容資訊 英文 480 Pages
商品交期: 最快1-2個工作天內
價格
如有價格方面的疑問請按下「詢問」鍵來信查詢
Back to Top
蛋白質、肽口服藥市場 Oral Proteins and Peptides Market (3rd Edition), 2018 - 2030
出版日期: 內容資訊: 英文 480 Pages
簡介

本報告提供蛋白質、肽口服藥市場現狀及今後10年的發展趨勢相關綜合分析、主要的案例研究及技術平台、競爭情形等分析彙整。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 低分子醫藥品的蛋白質/肽治療藥比較
  • 給藥途徑
  • 開發上的課題
  • 蛋白質、肽口服藥

第4章 概要、市場背景

  • 本章概要
  • 正在開發的蛋白質、肽口服藥
  • 開發平台分析

第5章 藥物簡介、市場預測

  • 簡介
  • 全體市場
  • Linaclotide(Linzess/Constella)
  • Plecanatide
  • Octreolin
  • Ostora
  • IN-105

第6章 案例研究:LIPROTAMASE、SANDIMMUNE、DDAVP

  • Liprotamase
  • Sandimmune
  • DDAVP/Minirin (去氨加壓素)

第7章 技術平台

  • 本章概要
  • Axcess (Proxima Concepts)
  • Peptelligence (Enteris Biopharma)
  • 胃腸道滲透增強技術,GIPET (Merrion Pharmaceuticals)
  • POD (蛋白質口服給藥)技術(Oramed Pharmaceuticals)
  • 多matrix system(Cosmo Pharmaceuticals)
  • 口服抗體平台(Avaxia Biologics)
  • Eligen (Emisphere Technologies)

第8章 近幾年的產業聯盟

  • 本章概要
  • 產業聯盟模式/契約
  • 利害關係者間的合資企業的普及
  • 產品開發、技術許可證、產品專利模式:受歡迎的合資企業模式
  • 在蛋白質、肽口服藥的領域最活躍的企業

第9章 創業投資支援

  • 本章概要
  • 蛋白質、肽口服藥市場上的投資、津貼的實例
  • 創業投資企業愈來愈受重視
  • 資金提供的實例:各資金提供方式的分佈情形
  • 資金提供額:各資金提供方式的分佈情形

第10章 SWOT分析

  • 本章概要
  • 優勢
  • 弱點
  • 機會
  • 威脅

第11章 結論

  • 來自複數的利害關係者的關心增加
  • 新技術的登場
  • 許多的適應症推薦的提供形態
  • 新興市場接近轉換點
  • 課題存在,可是能跨過

第12章 附錄1:資料表

第13章 附錄2:企業清單

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA100102

Protein and peptide-based therapeutics have been in use for more than three decades since the approval of recombinant human insulin, the first protein therapy, in 1982. Earlier, most biologic drugs were delivered through the subcutaneous route. However, over time, advances in delivery formulations have enabled the development of orally administrable versions of therapeutic proteins / peptides. Owing to numerous compelling reasons, the concept of oral delivery has gained significant traction. The first oral protein / peptide-based product candidate, Linzess®, was launched in 2012 in the US and EU. Recently, Trulance®, another orally administrable product was approved in the US (January 2017) for the treatment of chronic idiopathic constipation (CIC). In fact, in January 2018, Trulance® was approved for another indication, namely irritable bowel syndrome with constipation (IBS-C).

The growing popularity of this upcoming class of therapeutics has led to the development of several oral protein / peptide-based product candidates for the treatment of a myriad of diseases. In addition, the need for efficient and patient-friendly treatment options for chronic disorders, such as diabetes, is estimated to boost the demand for oral proteins and peptides in the coming years. Despite their clinical and commercial success, oral formulations of protein / peptide-based drugs have been associated with multiple drawbacks, such as concerns related to unwanted enzymatic degradation, inherent structural complexities, high manufacturing costs and low bioavailability. The aforementioned issues tend to have an impact on the overall efficacy of such products, thereby, limiting their therapeutic potential. This has prompted researchers to develop better technologies in order to improve product stability and therapeutic efficiency. The ongoing innovation has led to the discovery of novel biological targets, strengthening the research pipelines of various companies focused in this domain. Increasing research and development activities, and rising demand for effective drugs with better therapy adherence profiles are anticipated to encourage growth of the global oral proteins and peptides market in the coming years.

The 'Oral Proteins and Peptides Market (3rd Edition), 2018-2030' report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, featuring a comprehensive discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, including both small to mid-sized players and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 28% of drug candidates are presently in advanced stages of evaluation (phase II and above). Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of oral proteins / peptides, providing information on various drug developers, phase of development (clinical, preclinical or discovery stage) of product candidates, type of molecule (protein or peptide), biological target, mechanism of action, affiliated technology platform, key therapeutic area(s) and indication(s), and dosage.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of the various industry and non-industry players involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players that are involved in the development of oral proteins / peptides.
  • Details of recently held / upcomingconferences focused solely / partially on various aspects related to the oral delivery of proteins / peptides.
  • A detailed analysis identifying the key opinion leaders (KOLs) in the field of oral proteins / peptides. This features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers involved in the development of already marketed molecules in this domain.
  • Identification of the most commonly targeted therapeutic indications, and details of the oral proteins / peptides being developed against them. The study presents information on epidemiology, available diagnostic tests, and details of current treatment options and their side effects.
  • Comprehensive profiles of marketed and phase III drugs, highlighting their history of development, mechanism of action, dosage information (if available), manufacturing information (if available), current status of development, clinical trial information, key clinical trial results, historical sales (if marketed) and information on the developer.
  • A case study, featuring profiles of three of the most popular orally administrable protein / peptide-based drugs belonging to other drug classes, namely cyclic peptides and pancreatic enzyme replacement therapies (PERTs), which are either commercialized or under development. Each profile provides an overview of the drug, history of development, chemical structure and mechanism of action, dosage information (if marketed), clinical trial information (if the product is currently under development), patent portfolio (if available), and information on the other commercially available treatment options.
  • A review of the various oral drug delivery technology platforms that are being used for the development of product candidates in this domain, highlighting their key features and providing information on their developers. Specifically, for each technology platform, we have captured information on the various components of the technology, approach / system being used, type of formulation and type of molecules(s) that can be delivered using the technology.
  • Elaborate profiles of the technologies that are presently being used in the development of three or more products / product candidates (in both preclinical and clinical stages of development) with at least one candidate in the clinical stages of development, along with technologies for which the drugs are in advanced clinical stages of development (phase III and above). Each profile features an overview of the developer and technology, mechanism of action, key advantages, pipeline molecules developed using the technology and recent developments specific to the technology (acquisitions / mergers, collaborations and expansions).
  • An insightful 2X2 analysis of the different oral delivery technology platforms that are presently being utilized for the generation of oral proteins / peptides. The analysis is based on the supplier power (represented in terms of venture funding activity and company size) and product competitiveness (represented in terms of development activity (number of drugs in both preclinical / clinical stages of development), indication coverage, partnerships activity).
  • An analysis of the partnerships that have been established in the recent past, covering product development / commercialization agreements, R&D collaborations, technology licensing deals, manufacturing agreements, merger / acquisitions, product licensing deals, clinical trial collaborations and others.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.
  • A publication analysis, featuring inputs from close to 90 articles that have been published in 2017, highlighting the key focus areas of the ongoing research activity in this field.
  • An analysis depicting the prevalent and emerging trends related to this domain as represented on the social media platform, Twitter. In addition to providing information on quarterly trends related to the volume of tweets in 2017, the analysis highlights the most talked about biological targets, drug candidates, active players, technology platforms, disease indications, and therapeutic areas.
  • A detailed case study on protein / peptide contract manufacturing, featuring a list of over 140 CMOs that are currently offering contract manufacturing services for such products / product candidates.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall oral proteins / peptides market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the market based on [A] therapeutic areas (autoimmune disorders, bone disorders, digestive and gastrointestinal disorders, hormonal disorders, infectious diseases, metabolic disorders, urogenital disorders and others), [B] molecule type (protein and peptide), [C] technology platforms, [D] key players, and [E] geography (North America (the US, Canada and Mexico), Europe (EU5 countries), Asia-Pacific and RoW). To account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (Director and CEO, Tarix Orphan). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. Around 100 oral protein / peptide therapeutics are currently being developed across various preclinical / clinical stages for a diverse range of indications. Two products, namely Linzess® (Ironwood Pharmaceuticals) and Trulance® (Synergy Pharmaceuticals), are commercially available; of these, Trulance® was approved in January 2017. Nearly 41% of the pipeline molecules are under clinical development; of these, 8 molecules are being investigated in phase III and phase II/III, 18 molecules in phase II, 5 molecules in phase II (planned), 1 in phase I/II, and 9 molecules in phase I and phase I (planned) clinical trials. However, majority (57%) of the product candidates in the pipeline are still in the preclinical and discovery stages.
  • 2. 42% of the products in the development pipeline are designed to treat various metabolic disorders, including (in decreasing order of number of pipeline products) diabetes, obesity and non-alcoholic steatohepatitis (NASH). Nearly 15% of therapy candidates are being developed for the treatment of digestive and gastrointestinal disorders, including (in decreasing order of number of pipeline products) chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), opioid-induced constipation (OIC) and short bowel syndrome (SBS). Products are also being developed for other therapeutic areas, such as autoimmune disorders (9), infectious diseases (9), hormonal disorders (5), bone disorders (4), blood disorders (3), various oncological indications (2), respiratory disorders (2), urogenital disorders (2), genetic disorders (1) and neurodegenerative disorders (1).
  • 3. The market landscape is characterized by the presence of large (13, with more than 200 employees), mid-sized (12, with 50-200 employees) and small-sized companies (33, with less than 50 employees). Some of the prominent large companies engaged in this domain include (in alphabetical order)Chiasma Pharma, Ferring Pharmaceuticals, Ironwood Pharmaceuticals, Novo Nordisk and Sanofi Aventis. Similarly, mid-sized companies that are actively contributing to the development of oral protein / peptide-based product candidates include (in alphabetical order) Emisphere Technologies, Protagonist Therapeutics, Synergy Pharmaceuticals and Transgene Biotek. In addition, small companies, such as (in alphabetical order)Allena Pharmaceuticals, Biolingus, Enteris BioPharma, Longevity Biotech, Oramed Pharmaceuticals, Proxima Concepts and Rani Therapeutics, are also actively involved in this domain.
  • 4. Several universities / research organizations, either independently or in collaboration with industry players, have also contributed to the development of products in both preclinical and clinical studies. Examples include (in alphabetical order) Medical University of South Carolina, Monash University, National Institute of Diabetes and Digestive and Kidney Diseases, Niagara University and University of Montreal.
  • 5. To overcome the challenges related to the effective administration of oral biologics, several innovative technologies to formulate and deliver oral biologics are being developed. Notable examples of advanced drug delivery technologies include (in decreasing order of number of pipeline products) Robotic Pill Maker technology (Rani Therapeutics), Peptelligence® (Enteris BioPharma), AxcessTM oral drug delivery technology (Proxima Concepts), Oral Peptide Utility System (OPUS) technology (Biolingus), Sublingual Immunotherapy (SLIT) technology (Biolingus), and Oramed Protein Oral Delivery (PODTM) technology (Oramed Pharmaceuticals).
  • 6. Over 195 funding instances, amounting to USD 5.4 billion worth of capital, have taken place in this field in the last decade. Cherrystone Angel Group, Novartis Venture Fund, Third Security, MVM Life Science Partners, Venrock, ARCH Venture Partners, Ascent Biomedical Ventures, Boston Harbor Angels, F2 Ventures, Google Ventures, MPM Capital and Pharmstandard Internationalhave emerged as some of the prominent investors (in terms of number of funding instances).
  • 7. Since 2008, around 100 partnerships have been inked between various stakeholders within the industry; of these, 44 collaborations have been established since 2012. Approximately 39% of the deals were product development / commercialization agreements; recent examples include agreements between Carmot Therapeutics and Amgen (December 2017), Eli Lilly and KeyBioscience (June 2017), Protagonist Therapeutics and Janssen Biotech (May 2017), Enteris BioPharma and Sanofi (January 2017), Ironwood Pharmaceuticals and Allergan (January 2017), and Takeda Pharmaceuticals and PvP Biologics (January 2017). Other popular types of collaborations were R&D deals (25%), technology licensing agreements (9%), manufacturing agreements (8%), mergers / acquisitions (7%), product licensing agreements (6%) and clinical trial collaborations (5%). In terms of the number of deals signed in the given time period, Oramed Pharmaceuticals (8), Ironwood Pharmaceuticals (8), Merrion Pharmaceuticals (7), Enteris BioPharma (7) and Novo Nordisk (7), have emerged as the most active companies.
  • 8. With many candidates in late stages of development and increase in technological advancements, the market is likely to grow at a steady pace over the coming decade. North America and the EU5 presently dominate the market share and are expected to retain the leading position over the next decade. Within Asia-Pacific and RoW regions, India, Japan, Russia, Israel and Australia are expected to garner a growing share of the market by 2030.
  • 9. The two currently marketed drugs target digestive and gastrointestinal disorders, including CIC and IBS-C. With the anticipated approval of close to 20 additional drugs by 2030, the market is likely to be driven by four therapeutic areas, namely metabolic disorders (48%), digestive and gastrointestinal disorders (17%), autoimmune disorders (8%) and bone disorders (5%). In fact, specific products, being developed for indications with very large target patient populations, are anticipated to achieve blockbuster status (with sales over USD 1 billion) and become prime contributors to future revenues in the coming decade.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. A Detailed Comparison of Biologics and Small Molecules
  • 3.3. An Introduction to Proteins
    • 3.3.1. Protein Structure
    • 3.3.2. Classification
  • 3.4. An Introduction to Peptides
    • 3.4.1. Peptide Structure
    • 3.4.2. Classification
      • 3.4.2.1. Synthetic Peptides
      • 3.4.2.2. Recombinant Peptides
  • 3.5. Routes of Delivery for Proteins / Peptides
    • 3.5.1. Parenteral Systemic Delivery
      • 3.5.1.1. Intramuscular Route
      • 3.5.1.2. Intravenous Route
      • 3.5.1.3. Subcutaneous Route
    • 3.5.2. Non-Parenteral Systemic Delivery
      • 3.5.2.1. Buccal / Sublingual Route
      • 3.5.2.2. Intranasal Route
      • 3.5.2.3. Oral Route
      • 3.5.2.4. Ocular Route
      • 3.5.2.5. Pulmonary Route / Inhalation
      • 3.5.2.6. Rectal Route
      • 3.5.2.7. Transdermal Route
  • 3.6. Oral Delivery of Proteins / Peptides
    • 3.6.1. Evolution of Oral Delivery
    • 3.6.2. Key Advantages of Oral Delivery
    • 3.6.3. Key Challenges Associated with Oral Delivery
  • 3.7. Approaches Used for Structural and Bioavailability Enhancement
    • 3.7.1. Absorption Enhancers
    • 3.7.2. Chemical Modification
    • 3.7.3. Enzyme Inhibitors
    • 3.7.4. Muco-Adhesive Polymeric Systems
    • 3.7.5. Nanoparticular Delivery Systems
      • 3.7.5.1. Liposomes
      • 3.7.5.2. Nanoparticles / Microparticles
    • 3.7.6. Pro Drug Approach
    • 3.7.7. PEGylation
  • 3.8. Concluding Remarks

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Oral Proteins / Peptides: Development Pipeline
    • 4.2.1. Distribution by Phase of Development
    • 4.2.2. Distribution by Type of Molecule
    • 4.2.3. Distribution by Therapeutic Areas
    • 4.2.4. Distribution by Key Biological Targets
    • 4.2.5. Distribution by Key Technology Platforms
    • 4.2.6. Distribution by Leading Players
  • 4.3. Oral Proteins / Peptides: Terminated / Discontinued Candidates

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Oral Proteins / Peptides Pipeline: Target Therapeutic Areas
  • 5.3. Oral Proteins / Peptides Pipeline: Developer Landscape
  • 5.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players)
  • 5.5. Oral Proteins / Peptides: Recent / Upcoming Conferences

6. KOL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Current Research Landscape
  • 6.3. Linzess® and Trulance®: Key Opinion Leaders
  • 6.4. Most Prominent Key Opinion Leaders

7. KEY THERAPEUTIC AREAS

  • 7.1. Chapter Overview
  • 7.2. Metabolic Disorders
    • 7.2.1. Diabetes
      • 7.2.1.1. Disease Description
      • 7.2.1.2. Associated Health Risks / Complications
      • 7.2.1.3. Epidemiology
      • 7.2.1.4. Disease Diagnosis
      • 7.2.1.5. Current Treatment Options
        • 7.2.1.5.1. Insulin Therapies
        • 7.2.1.5.2. Non-Insulin Therapies
      • 7.2.1.6. Side Effects of Current Treatment Options
      • 7.2.1.7. Oral Proteins / Peptides for Diabetes
    • 7.2.2. Obesity
      • 7.2.2.1. Disease Description
      • 7.2.2.2. Epidemiology
      • 7.2.2.3. Current Treatment Options
      • 7.2.2.4. Side Effects of Current Treatment Options
      • 7.2.2.5. Oral Proteins / Peptides for Obesity
    • 7.2.3. Non-alcoholic Steatohepatitis (NASH)
      • 7.2.3.1. Disease Description
      • 7.2.3.2. Epidemiology
      • 7.2.3.3. Current Treatment Options
      • 7.2.3.4. Oral Proteins / Peptides for NASH
  • 7.3. Digestive and Gastrointestinal Disorders
    • 7.3.1. Ulcerative Colitis
      • 7.3.1.1. Disease Description
      • 7.3.1.2. Epidemiology
      • 7.3.1.3. Current Treatment Options
      • 7.3.1.4. Side Effects of Current Treatment Options
      • 7.3.1.5. Oral Proteins / Peptides for Ulcerative Colitis
    • 7.3.2. Crohn's Disease
      • 7.3.2.1. Disease Description
      • 7.3.2.2. Epidemiology
      • 7.3.2.3. Current Treatment Options
      • 7.3.2.4. Side Effects of Current Treatment Options
      • 7.3.2.5. Oral Proteins / Peptides for Crohn's Disease
  • 7.4. Infectious Diseases
    • 7.4.1. C. difficile Infections (CDIs)
      • 7.4.1.1. Disease Description
      • 7.4.1.2. Epidemiology
      • 7.4.1.3. Disease Diagnosis
      • 7.4.1.4. Current Treatment Options
      • 7.4.1.5. Side Effects of Current Treatment Options
      • 7.4.1.6. Oral Proteins / Peptides for CDIs
  • 7.5. Autoimmune Disorders
    • 7.5.1. Celiac Disease
      • 7.5.1.1. Disease Description
      • 7.5.1.2. Epidemiology
      • 7.5.1.3. Disease Diagnosis
      • 7.5.1.4. Current Treatment Options
      • 7.5.1.5. Oral Proteins / Peptides for Celiac Disease
  • 7.6. Hormonal Disorders
    • 7.6.1. Acromegaly
      • 7.6.1.1. Disease Description
      • 7.6.1.2. Epidemiology
      • 7.6.1.3. Disease Diagnosis
      • 7.6.1.4. Current Treatment Options
      • 7.6.1.5. Side Effects of Current Treatment Options
      • 7.6.1.6. Oral Proteins / Peptides for Acromegaly
  • 7.7. Bone Disorders
    • 7.7.1. Osteoporosis
      • 7.7.1.1. Disease Description
      • 7.7.1.2. Epidemiology
      • 7.7.1.3. Disease Diagnosis
      • 7.7.1.4. Current Treatment Options
      • 7.7.1.5. Side Effects of Current Treatment Options
      • 7.7.1.6. Oral Proteins / Peptides for Osteoporosis

8. MARKETED AND LATE-STAGE DRUG PROFILES

  • 8.1. Chapter Overview
  • 8.2. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
    • 8.2.1. Overview
    • 8.2.2. History of Development
    • 8.2.3. Mechanism of Action
    • 8.2.4. Dosage Form, Treatment Regimen and Price
    • 8.2.5. Manufacturing Information
    • 8.2.6. Current Status of Development
    • 8.2.7. Clinical Studies
    • 8.2.8. Key Clinical Trial Results
    • 8.2.9. Historical Sales
    • 8.2.10. Developer Overview
  • 8.3. Trulance® / Plecanatide (Synergy Pharmaceuticals)
    • 8.3.1. Overview
    • 8.3.2. History of Development
    • 8.3.3. Mechanism of Action
    • 8.3.4. Dosage Form, Treatment Regimen and Price
    • 8.3.5. Manufacturing Information
    • 8.3.6. Current Status of Development
    • 8.3.7. Clinical Studies
    • 8.3.8. Key Clinical Trial Results
    • 8.3.9. Historical Sales
    • 8.3.10. Developer Overview
  • 8.4. TBRIA™ / OSTORA / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
    • 8.4.1. Overview
    • 8.4.2. History of Development
    • 8.4.3. Mechanism of Action
    • 8.4.4. Manufacturing Information
    • 8.4.5. Current Status of Development
    • 8.4.6. Clinical Studies
    • 8.4.7. Key Clinical Trial Results
    • 8.4.8. Developer Overview
  • 8.5. ALLN-177 (Allena Pharmaceuticals)
    • 8.5.1. Overview
    • 8.5.2. History of Development
    • 8.5.3. Mechanism of Action
    • 8.5.4. Current Status of Development
    • 8.5.5. Clinical Studies
    • 8.5.6. Key Clinical Trial Results
    • 8.5.7. Developer Overview
  • 8.6. Mycapssa™ / Octreolin / Oral Octreotide (Chiasma Pharma)
    • 8.6.1. Overview
    • 8.6.2. History of Development
    • 8.6.3. Mechanism of Action
    • 8.6.4. Manufacturing Information
    • 8.6.5. Current Status of Development
    • 8.6.6. Clinical Studies
    • 8.6.7. Key Clinical Trial Results
    • 8.6.8. Developer Overview
  • 8.7. NTRA-2112 (Nutrinia)
    • 8.7.1. Overview
    • 8.7.2. Mechanism of Action
    • 8.7.3. Current Status of Development
    • 8.7.4. Clinical Studies
    • 8.7.5. Developer Overview
  • 8.8. Oral Semaglutide / NN9924 / OG217SC (Novo Nordisk / Emisphere Technologies)
    • 8.8.1. Overview
    • 8.8.2. History of Development
    • 8.8.3. Mechanism of Action
    • 8.8.4. Manufacturing Information
    • 8.8.5. Current Status of Development
    • 8.8.6. Clinical Studies
    • 8.8.7. Key Clinical Trial Results
    • 8.8.8. Developer Overview

9. CASE STUDIES: MINIRIN®, SANDIMMUNE® AND SOLLPURA®

  • 9.1. Chapter Overview
  • 9.2. Minirin® / DDAVP (Ferring Pharmaceuticals)
    • 9.2.1. Overview
    • 9.2.2. History of Development
    • 9.2.3. Chemical Structure and Mechanism of Action
    • 9.2.4. Dosage Form, Treatment Regimen and Price
    • 9.2.5. Patent Portfolio
    • 9.2.6. Competitive Landscape
  • 9.3. Sandimmune® / Neoral® (Novartis)
    • 9.3.1. Overview
    • 9.3.2. History of Development
    • 9.3.3. Mechanism of Action
    • 9.3.4. Dosage Form, Treatment Regimen and Price
    • 9.3.5. Patent Portfolio
    • 9.3.6. Competitive Landscape
  • 9.4. Sollpura® / Liprotamase (Anthera Pharmaceuticals)
    • 9.4.1. Overview
    • 9.4.2. History of Development
    • 9.4.3. Chemical Structure and Mechanism of Action
    • 9.4.4. Current Status of Development
    • 9.4.5. Clinical Studies
    • 9.4.6. Competitive Landscape

10. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS

  • 10.1. Chapter Overview
  • 10.2. Oral Drug Delivery: List of Technology Platforms
  • 10.3. Technology Profiles
    • 10.3.1. Axcess™ Oral Drug Delivery Technology (Proxima Concepts)
      • 10.3.1.1. Developer Overview
      • 10.3.1.2. Technology Overview
      • 10.3.1.3. Drug Delivery Mechanism
      • 10.3.1.4. Key Advantages
      • 10.3.1.5. Oral Proteins / Peptides Pipeline
      • 10.3.1.6. Collaborations
    • 10.3.2. Eligen™ Technology (Emisphere Technologies)
      • 10.3.2.1. Developer Overview
      • 10.3.2.2. Technology Overview
      • 10.3.2.3. Drug Delivery Mechanism
      • 10.3.2.4. Key Advantages
      • 10.3.2.5. Oral Proteins / Peptides Pipeline
      • 10.3.2.6. Collaborations
    • 10.3.3. Entera Technology (Entera Bio)
      • 10.3.3.1. Developer Overview
      • 10.3.3.2. Technology Overview
      • 10.3.3.3. Drug Delivery Mechanism
      • 10.3.3.4. Key Advantages
      • 10.3.3.5. Oral Proteins / Peptides Pipeline
    • 10.3.4. NTRA Oral Delivery Technology (Nutrinia)
      • 10.3.4.1. Developer Overview
      • 10.3.4.2. Technology Overview
      • 10.3.4.3. Drug Delivery Mechanism
      • 10.3.4.4. Key Advantages
      • 10.3.4.5. Oral Proteins / Peptides Pipeline
    • 10.3.5. Peptelligence® Technology (Enteris BioPharma)
      • 10.3.5.1. Developer Overview
      • 10.3.5.2. Technology Overview
      • 10.3.5.3. Drug Delivery Mechanism
      • 10.3.5.4. Key Advantages
      • 10.3.5.5. Oral Proteins / Peptides Pipeline
      • 10.3.5.6. Collaborations
    • 10.3.6. Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
      • 10.3.6.1. Developer Overview
      • 10.3.6.2. Technology Overview
      • 10.3.6.3. Drug Delivery Mechanism
      • 10.3.6.4. Key Advantages
      • 10.3.6.5. Oral Proteins / Peptides Pipeline
    • 10.3.7. Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)
      • 10.3.7.1. Developer Overview
      • 10.3.7.2. Technology Overview
      • 10.3.7.3. Drug Delivery Mechanism
      • 10.3.7.4. Key Advantages
      • 10.3.7.5. Oral Proteins / Peptides Pipeline
    • 10.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)
      • 10.3.8.1. Developer Overview
      • 10.3.8.2. Technology Overview
      • 10.3.8.3. Drug Delivery Mechanism
      • 10.3.8.4. Key Advantages
      • 10.3.8.5. Oral Proteins / Peptides Pipeline

11. PRODUCT COMPETITIVENESS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Product Competitiveness Analysis: Key Technologies

12. FUNDING AND INVESTMENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Types of Funding
  • 12.3. Oral Proteins / Peptides: Funding and Investment Analysis
    • 12.3.1. Analysis by Cumulative Number of Funding Instances
    • 12.3.2. Analysis by Cumulative Amount Invested
    • 12.3.3. Analysis by Type of Funding
    • 12.3.4. Analysis by Most Active Players
    • 12.3.5. Analysis by Most Active Investors
  • 12.4. Concluding Remarks

13. RECENT COLLABORATIONS

  • 13.1. Chapter Overview
  • 13.2. Partnership Models
  • 13.3. Oral Proteins / Peptides: List of Partnerships
  • 13.4. Partnership Analysis
    • 13.4.1. Analysis by Year of Partnerships
    • 13.4.2. Analysis by Type of Partnerships
    • 13.4.3. Most Active Players: Analysis by Number of Partnerships

14. PUBLICATION ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Oral Proteins / Peptides: List of Publications, 2017
    • 14.2.1. Quarter-Wise Trend (Q1-Q4 2017)
    • 14.2.2. Analysis by Type of Study
    • 14.2.3. Analysis by Key Biological Targets
    • 14.2.4. Analysis by Key Journals

15. EMERGING TRENDS ON SOCIAL MEDIA

  • 15.1. Chapter Overview
  • 15.2. Oral Proteins / Peptides: Trends on Twitter
  • 15.3. Year-Wise Activity Analysis (2013-2017)
  • 15.4. Popular Keywords
  • 15.5. Popular Therapeutic Areas
  • 15.6. Popular Biological Targets
  • 15.7. Popular Technology Platforms
  • 15.8. Popular Drugs
  • 15.9. Popular Players

16. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scope and Limitations
  • 16.3. Forecast Methodology
  • 16.4. Overall Oral Proteins / Peptides Market, 2018-2030
    • 16.4.1. Oral Proteins / Peptides Market: Distribution by Therapeutic Area
    • 16.4.2. Oral Proteins / Peptides Market: Distribution by Molecule Type
    • 16.4.3. Oral Proteins / Peptides Market: Distribution by Key Players
    • 16.4.4. Oral Proteins / Peptides Market: Distribution by Technology Platforms
    • 16.4.5. Oral Proteins / Peptides Market: Distribution by Geography
  • 16.5. Oral Proteins / Peptides Market: Product-Wise Sales Forecasts
    • 16.5.1. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
      • 16.5.1.1. Target Patient Population
      • 16.5.1.2. Sales Forecast
    • 16.5.2. Trulance® / Plecanatide (Synergy Pharmaceuticals)
      • 16.5.2.1. Target Patient Population
      • 16.5.2.2. Sales Forecast
    • 16.5.3. TBRIA™ / OSTORA / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
      • 16.5.3.1. Target Patient Population
      • 16.5.3.2. Sales Forecast
    • 16.5.4. ALLN-177 (Allena Pharmaceuticals)
      • 16.5.4.1. Target Patient Population
      • 16.5.4.2. Sales Forecast
    • 16.5.5. Mycapssa™ / Octreolin (Chiasma Pharma)
      • 16.5.5.1. Target Patient Population
      • 16.5.5.2. Sales Forecast
    • 16.5.6. NTRA-2112 (Nutrinia)
      • 16.5.6.1. Target Patient Population
      • 16.5.6.2. Sales Forecast
    • 16.5.7. Oral Semaglutide / NN9924 / OG217SC (Novo Nordisk / Emisphere Technologies)
      • 16.5.7.1. Target Patient Population
      • 16.5.7.2. Sales Forecast
    • 16.5.8. Larazotide INN-202 (Innovate Biopharmaceuticals)
      • 16.5.8.1. Target Patient Population
      • 16.5.8.2. Sales Forecast
    • 16.5.9. NTRA-9620 (Nutrinia)
      • 16.5.9.1. Target Patient Population
      • 16.5.9.2. Sales Forecast
    • 16.5.10. AG013 (Oragenics / Intrexon)
      • 16.5.10.1. Target Patient Population
      • 16.5.10.2. Sales Forecast
    • 16.5.11. IMM-124E (Immuron)
      • 16.5.11.1. Target Patient Population
      • 16.5.11.2. Sales Forecast
    • 16.5.12. OPRX-106 (Protalix Biotherapeutics)
      • 16.5.12.1. Target Patient Population
      • 16.5.12.2. Sales Forecast
    • 16.5.13. KORSUVATM / Oral CR845 / Difelikefalin (Enteris BioPharma / Cara Therapeutics)
      • 16.5.13.1. Target Patient Population
      • 16.5.13.2. Sales Forecast
    • 16.5.14. Oral HDV Insulin (Diasome Pharmaceuticals)
      • 16.5.14.1. Target Patient Population
      • 16.5.14.2. Sales Forecast
    • 16.5.15. ORMD-0801 (Oramed Pharmaceuticals)
      • 16.5.15.1. Target Patient Population
      • 16.5.15.2. Sales Forecast
    • 16.5.16. Oshadi Icp Oral Insulin (Oshadi Drug Administration)
      • 16.5.16.1. Target Patient Population
      • 16.5.16.2. Sales Forecast
    • 16.5.17. Ovarest® / Oral Leuprolide Tablet (Enteris BioPharma)
      • 16.5.17.1. Target Patient Population
      • 16.5.17.2. Sales Forecast
    • 16.5.18. PTG-100 (Protagonist Therapeutics)
      • 16.5.18.1. Target Patient Population
      • 16.5.18.2. Sales Forecast
    • 16.5.19. SYN-004 / Ribaxamase (Synthetic Biologics)
      • 16.5.19.1. Target Patient Population
      • 16.5.19.2. Sales Forecast
    • 16.5.20. V565 (VHsquared)
      • 16.5.20.1. Target Patient Population
      • 16.5.20.2. Sales Forecast

17. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING

  • 17.1. Chapter Overview
  • 17.2. Key Steps Involved in Protein / Peptide Manufacturing
  • 17.3. Challenges Associated with Protein / Peptide Manufacturing
  • 17.4. Current Scenario of Protein / Peptide Manufacturing
  • 17.5. Growing Demand for Contract Manufacturing
    • 17.5.1. Selecting A Suitable CMO Partner
    • 17.5.2. List of Protein / Peptide CMOs

18. SWOT ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Comparison of SWOT Factors

19. CONCLUSION

  • 19.1. Advances in Oral Drug Delivery have Enabled the Development of Protein / Peptide Therapeutics Offering Improved Patient Compliance
  • 19.2. The Field is Characterized by a Promising Development Pipeline, Featuring Molecules Against a Diverse Range of Biological Targets
  • 19.3. Oral Protein / Peptide-based Therapeutics are being Designed to Treat a Wide Spectrum of Disease Indications; however, the Primary Focus is on Metabolic and Gastrointestinal Disorders
  • 19.4. In Addition to Established Players, a Number of Start-ups, Backed by Venture Capital Investors, are Making Significant Contributions in this Domain
  • 19.5. Several Stakeholders have Entered into Strategic Alliances Aimed at Promoting Research and Advancing Product Development Efforts
  • 19.6. Post the Approval of Multiple Late-Phase Product Candidates, the Market is Anticipated to Grow Significantly in the Foreseen Future
  • 19.7. Concluding Remarks

20. EXECUTIVE INSIGHTS

  • 20.1. Chapter Overview
  • 20.2. Anthera Pharmaceuticals
    • 20.2.1. Company Snapshot
    • 20.2.2. Interview Transcript: Dinesh Srinivasan, Director
  • 20.3. Carmot Therapeutics
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Stig K Hansen, CEO
  • 20.4. IGY Life Sciences and Technology
    • 20.4.1. Company Snapshot
    • 20.4.2. Interview Transcript: Terry Dyck, President and CEO
  • 20.5. Tarix Orphan
    • 20.5.1. Company Snapshot
    • 20.5.2. Interview Transcript: Richard Franklin, Director and CEO

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES

List of Figures

  • Figure 3.1 Biologics and Small Molecules: Comparison of Key Characteristics
  • Figure 3.2 Classification of Proteins
  • Figure 3.3 Routes of Delivery for Proteins / Peptides
  • Figure 3.4 Peptides: Distribution by Route of Administration
  • Figure 3.5 Oral Route of Drug Delivery: An Evolving Trend
  • Figure 3.6 Mechanisms of Drug Transport through the Intestinal Epithelium
  • Figure 4.1 Oral Proteins / Peptides: Distribution by Phase of Development
  • Figure 4.2 Oral Proteins / Peptides: Distribution by Type of Molecule
  • Figure 4.3 Oral Proteins / Peptides: Distribution by Therapeutic Area
  • Figure 4.4 Oral Proteins / Peptides: Distribution by Key Biological Targets
  • Figure 4.5 Oral Proteins / Peptides: Distribution by Key Technology Platforms
  • Figure 4.6 Oral Proteins / Peptides: Distribution by Leading Players
  • Figure 5.1 Oral Proteins / Peptides Grid Analysis: Distribution by Therapeutic Area, Type of Molecule and Phase of Development
  • Figure 5.2 Oral Proteins / Peptides Developer Landscape: Distribution by Company Size and Phase of Development
  • Figure 5.3 Oral Proteins / Peptides Regional Landscape (Industry Players): Distribution by Company Location and Pipeline Strength
  • Figure 5.4 Oral Proteins / Peptides Recent / Upcoming Conferences: Distribution by Year and Geography
  • Figure 5.5 Oral Proteins / Peptides Recent / Upcoming Conferences: Regional Map
  • Figure 6.1 Linzess® and Trulance®: Mapping Prominent Researchers
  • Figure 6.2 Oral Proteins / Peptides: Prominent Key Opinion Leaders
  • Figure 7.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
  • Figure 7.2 Non-Insulin Therapies for Diabetes
  • Figure 8.1 Linzess®: Historical Sales, 2013-2017 (USD Million)
  • Figure 8.2 Trulance®: Historical Sales, Q1 2017-Q3 2017 (USD Million)
  • Figure 8.3 Trulance®: Mechanism of Action
  • Figure 10.1 Axcess™ Oral Drug Delivery Technology: Components of Tablet
  • Figure 10.2 Peptelligence® Technology: Components of Enteric-Coated Tablet
  • Figure 10.3 Peptelligence® Technology: Drug Delivery Mechanism
  • Figure 11.1 Oral Drug Delivery Technology Platforms: Product Competitiveness Analysis
  • Figure 12.1 Oral Proteins / Peptides: Cumulative Number of Funding Instances, Pre-2008-2018
  • Figure 12.2 Oral Proteins / Peptides: Distribution of Amount Invested by Year, Pre-2008-2018 (USD Million)
  • Figure 12.3 Oral Proteins / Peptides: Distribution by Type of Funding, Pre-2008-2018
  • Figure 12.4 Oral Proteins / Peptides: Distribution of Total Amount Invested by Type of Funding, Pre-2008-2018 (USD Million)
  • Figure 12.5 Oral Proteins / Peptides: Most Active Players by Number of Funding Instances
  • Figure 12.6 Oral Proteins / Peptides: Most Active Investors by Number of Funding Instances
  • Figure 12.7 Oral Proteins / Peptides: Funding and Investment Summary
  • Figure 13.1 Oral Proteins / Peptides Partnerships: Cumulative Trend by Year (Pre-2008-2017)
  • Figure 13.2 Oral Proteins / Peptides Partnerships: Distribution by Type
  • Figure 13.3 Oral Proteins / Peptides Partnerships: Most Active Players
  • Figure 14.1 Publication Analysis: Cumulative Quarter-Wise Trend (Q1-Q4 2017)
  • Figure 14.2 Publication Analysis: Distribution by Type of Study
  • Figure 14.3 Publication Analysis: Distribution by Key Biological Targets
  • Figure 14.4 Publication Analysis: Distribution by Key Journals
  • Figure 15.1 Oral Proteins / Peptides: Trends on Twitter (2013-2017)
  • Figure 15.2 Oral Proteins / Peptides: Year-Wise Activity Analysis by Volume of Tweets (2013-2017)
  • Figure 15.3 Oral Proteins / Peptides: Popular Keywords on Twitter (2013-2017)
  • Figure 15.4 Oral Proteins / Peptides: Popular Therapeutic Areas on Twitter
  • Figure 15.5 Oral Proteins / Peptides: Popular Biological Targets on Twitter
  • Figure 15.6 Oral Proteins / Peptides: Popular Technology Platforms on Twitter
  • Figure 15.7 Oral Proteins / Peptides: Popular Drugs on Twitter
  • Figure 15.8 Oral Proteins / Peptides: Popular Players on Twitter
  • Figure 16.1 Overall Oral Proteins / Peptides Market, 2018-2030: Base Scenario (USD Billion)
  • Figure 16.2 Oral Proteins / Peptides Market: Market Attractiveness Analysis by Therapeutic Area, 2018 and 2030 (USD Billion)
  • Figure 16.3 Oral Proteins / Peptides Market: Distribution by Key Players, 2018, 2024 and 2030 (USD Billion)
  • Figure 16.4 Oral Proteins / Peptides Market: Distribution by Technology Platforms, 2018, 2024 and 2030 (USD Billion)
  • Figure 16.5 Oral Proteins / Peptides Market: Distribution by Geography, 2018, 2024 and 2030 (USD Billion)
  • Figure 16.6 Linzess® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.7 Trulance® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.8 TBRIA™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.9 ALLN-177 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.10 Mycapssa™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.11 NTRA-2112 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.12 Oral Semaglutide Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.13 Larazotide INN-202 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.14 NTRA-9620 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.15 AG013 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.16 IMM-124E Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.17 OPRX-106 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.18 KORSUVATM Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.19 Oral HDV Insulin Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.20 ORMD-0801 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.21 Oshadi Icp Oral Insulin Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.22 Ovarest® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.23 PTG-100 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.24 SYN-004 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 16.25 V565 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 17.1 Key Steps Involved in the Manufacturing of Biologics
  • Figure 17.2 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2017)
  • Figure 17.3 Factors for Selecting a CMO Partner
  • Figure 18.1 Oral Proteins / Peptides SWOT Analysis: Overview
  • Figure 18.2 Comparison of SWOT Factors by Potential Impact
  • Figure 18.3 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 19.1 Oral Proteins / Peptides Market, Conservative, Base and Optimistic Scenarios, 2018, 2024 and 2030 (USD Billion)

List of Tables

  • Table 3.1 Routes of Delivery for Proteins / Peptides: Comparison of Key Characteristics
  • Table 4.1 Oral Proteins / Peptides: Development Pipeline
  • Table 4.2 List of Terminated / Withdrawn Oral Proteins / Peptides
  • Table 5.1 Oral Proteins / Peptides: Recent / Future Conferences, 2014-2018
  • Table 7.1 Diabetes: Current Treatment Options
  • Table 7.2 Diabetes: Side Effects of Current Treatment Options
  • Table 7.3 Diabetes: Oral Proteins / Peptides Pipeline
  • Table 7.4 Obesity: Side Effects of Current Treatment Options
  • Table 7.5 Obesity: Oral Proteins / Peptides Pipeline
  • Table 7.6 NASH: Oral Proteins / Peptides Pipeline
  • Table 7.7 Ulcerative Colitis: Current Treatment Options
  • Table 7.8 Ulcerative Colitis: Side Effects of Current Treatment Options
  • Table 7.9 Ulcerative Colitis: Oral Proteins / Peptides Pipeline
  • Table 7.10 Crohn's Disease: Current Treatment Options
  • Table 7.11 Crohn's Disease: Side Effects of Current Treatment Options
  • Table 7.12 Crohn's Disease: Oral Proteins / Peptides Pipeline
  • Table 7.13 CDIs: Diagnostic Testing
  • Table 7.14 CDIs: Severity Scoring System and Treatment Options
  • Table 7.15 CDIs: Side Effects of Current Treatment Options
  • Table 7.16 CDIs: Oral Proteins / Peptides Pipeline
  • Table 7.17 Celiac Disease: Oral Proteins / Peptides Pipeline
  • Table 7.18 Acromegaly: Current Treatment Options
  • Table 7.19 Acromegaly: Side Effects of Current Treatment Options
  • Table 7.20 Acromegaly: Oral Proteins / Peptides Pipeline
  • Table 7.21 Osteoporosis: Current Treatment Options
  • Table 7.22 Osteoporosis: Side Effects of Current Treatment Options
  • Table 7.23 Osteoporosis: Oral Proteins / Peptides Pipeline
  • Table 8.1 Oral Peptides / Proteins: List of Drugs Profiled
  • Table 8.2 Linzess®: Dosage Details
  • Table 8.3 Linzess®: Current Status of Development
  • Table 8.4 Linzess®: Clinical Trials
  • Table 8.5 Linzess®: Results of Phase III Clinical Trial for CIC
  • Table 8.6 Ironwood Pharmaceuticals: Key Highlights
  • Table 8.7 Trulance®: Current Status of Development
  • Table 8.8 Trulance®: Clinical Trials
  • Table 8.9 Synergy Pharmaceuticals: Key Highlights
  • Table 8.10 TBRIA™: Current Status of Development
  • Table 8.11 TBRIA™: Clinical Trials
  • Table 8.12 TBRIA™: Results of Phase III ORACAL Clinical Trial
  • Table 8.13 Tarsa Therapeutics: Key Highlights
  • Table 8.14 ALLN-177: Current Status of Development
  • Table 8.16 ALLN-177: Clinical Trials
  • Table 8.17 ALLN-177: Results of Phase II Clinical Trial for Enteric Hyperoxaluria
  • Table 8.18 Allena Pharmaceuticals: Key Highlights
  • Table 8.19 Mycapssa™: Current Status of Development
  • Table 8.20 Mycapssa™: Clinical Trials
  • Table 8.21 Mycapssa™: Results of Phase III Clinical Trial for Acromegaly
  • Table 8.22 Chiasma Pharma: Key Highlights
  • Table 8.23 NTRA-2112: Current Status of Development
  • Table 8.24 NTRA-2112: Clinical Trials
  • Table 8.25 Nutrinia: Key Highlights
  • Table 8.26 Oral Semaglutide: Current Status of Development
  • Table 8.27 Oral Semaglutide: Clinical Trials
  • Table 8.28 Novo Nordisk: Key Highlights
  • Table 9.1 Oral Proteins / Peptides: List of Other Associated Drugs
  • Table 9.2 Minirin®: Generic Versions
  • Table 9.3 Minirin®: Dosage Details
  • Table 9.4 Minirin®: Price of Tablets
  • Table 9.5 Minirin®: Patent Portfolio
  • Table 9.6 Minirin®: Competitive Landscape
  • Table 9.7 Sandimmune® / Neoral®: Generic Versions
  • Table 9.8 Sandimmune® / Neoral®: Dosage Details
  • Table 9.9 Neoral®: Patent Portfolio
  • Table 9.10 Sandimmune® / Neoral®: Competitive Landscape
  • Table 9.11 Sollpura®: Mechanism of Action
  • Table 9.12 Sollpura®: Current Status of Development
  • Table 9.13 Sollpura®: Clinical Trials
  • Table 9.14 Sollpura®: Current Treatment Options
  • Table 10.1 Oral Delivery Technology Platforms: Comparison of Key Features
  • Table 10.3 Axcess™ Technology: Oral Proteins / Peptides Pipeline
  • Table 10.4 Eligen™ Technology: Oral Proteins / Peptides Pipeline
  • Table 10.5 Entera Technology: Oral Proteins / Peptides Pipeline
  • Table 10.6 NTRA Oral Delivery Technology: Oral Proteins / Peptides Pipeline
  • Table 10.7 Peptelligence® Technology: Oral Proteins / Peptides Pipeline
  • Table 10.8 POD™ Technology: Oral Proteins / Peptides Pipeline
  • Table 10.9 TPE® Technology: Oral Proteins / Peptides Pipeline
  • Table 10.10 Uroguanylin Analogue Platform: Oral Proteins / Peptides Pipeline
  • Table 12.1 Oral Proteins / Peptides: Funding and Investment Analysis
  • Table 12.2 Oral Proteins / Peptides: Summary of Investments
  • Table 13.1 Oral Proteins / Peptides: Recent Partnerships
  • Table 14.1 Oral Proteins / Peptides: List of Publications, 2017
  • Table 16.1 Oral Proteins / Peptides Market: Potential Candidates
  • Table 16.2 Oral Proteins / Peptides Forecast Assumptions: Price Estimation in Key Geographies
  • Table 16.3 Oral Proteins / Peptides Forecast Assumptions: Growth Rate Estimation by Key Therapeutic Areas
  • Table 16.4 Oral Proteins / Peptides Forecast Assumptions: Penetration Estimation by Key Therapeutic Areas (by 2030)
  • Table 16.5 Linzess®: Target Patient Population
  • Table 16.6 Trulance®: Target Patient Population
  • Table 16.7 TBRIA™: Target Patient Population
  • Table 16.8 ALLN-177: Target Patient Population
  • Table 16.9 Mycapssa™: Target Patient Population
  • Table 16.10 NTRA-2112: Target Patient Population
  • Table 16.11 Oral Semaglutide: Target Patient Population
  • Table 16.12 Larazotide INN-202: Target Patient Population
  • Table 16.13 NTRA-9620: Target Patient Population
  • Table 16.14 AG013: Target Patient Population
  • Table 16.15 IMM-124E: Target Patient Population
  • Table 16.16 OPRX-106: Target Population
  • Table 16.17 Korsuva™: Target Patient Population
  • Table 16.18 Oral HDV Insulin: Target Patient Population
  • Table 16.19 ORMD-0801: Target Patient Population
  • Table 16.20 Oshadi Icp Oral Insulin: Target Patient Population
  • Table 16.21 Ovarest®: Target Patient Population
  • Table 16.22 PTG-100: Target Patient Population
  • Table 16.23 SYN-004: Target Patient Population
  • Table 16.24 V565: Target Patient Population
  • Table 17.1 List of Contract Manufacturers Involved in Proteins / Peptides Manufacturing
  • Table 20.1 Anthera Pharmaceuticals: Key Highlights
  • Table 20.2 Carmot Therapeutics: Key Highlights
  • Table 20.3 IGY Life Sciences and Technology: Key Highlights
  • Table 20.4 Tarix Orphan: Key Highlights
  • Table 21.1 Drug Delivery: Distribution by Route of Administration
  • Table 21.2 Oral Proteins / Peptides: Distribution by Phase of Development
  • Table 21.3 Oral Proteins / Peptides: Distribution by Type of Molecule
  • Table 21.4 Oral Proteins / Peptides: Distribution by Therapeutic Areas
  • Table 21.5 Oral Proteins / Peptides: Distribution by Key Biological Targets
  • Table 21.6 Oral Proteins / Peptides: Distribution by Key Technology Platforms
  • Table 21.7 Oral Proteins / Peptides: Distribution by Leading Players
  • Table 21.8 Oral Proteins / Peptides Recent / Upcoming Conferences: Distribution by Year and Geography
  • Table 21.9 Linzess®: Historical Sales, 2013-2017 (USD Million)
  • Table 21.10 Trulance®: Historical Sales, Q1 2017-Q3 2017 (USD Million)
  • Table 21.11 Oral Proteins / Peptides: Cumulative Number of Funding Instances, Pre-2008-2018
  • Table 21.12 Oral Proteins / Peptides: Distribution of Amount Invested by Year, Pre-2008-2018 (USD Million)
  • Table 21.13 Oral Proteins / Peptides: Distribution by Type of Funding, Pre-2008-2018
  • Table 21.14 Oral Proteins / Peptides: Distribution of Total Amount Invested by Type of Funding, Pre-2008-2018 (USD Million)
  • Table 21.15 Oral Proteins / Peptides: Most Active Players by Number of Funding Instances
  • Table 21.16 Oral Proteins / Peptides: Most Active Investors by Number of Funding Instances
  • Table 21.17 Oral Proteins / Peptides Partnerships: Cumulative Trend by Year (Pre-2008-2017)
  • Table 21.18 Oral Proteins / Peptides Partnerships: Distribution by Type of Partnership
  • Table 21.19 Oral Proteins / Peptides Partnerships: Most Active Players
  • Table 21.20 Publication Analysis: Cumulative Quarter-Wise Trend (Q1-Q4 2017)
  • Table 21.21 Publication Analysis: Distribution by Type of Study
  • Table 21.22 Publication Analysis: Distribution by Key Biological Targets
  • Table 21.23 Publication Analysis: Distribution by Key Journals
  • Table 21.24 Oral Proteins / Peptides: Year-Wise Activity Analysis by Volume of Tweets (2013-2017)
  • Table 21.25 Overall Oral Proteins / Peptides Market, 2018-2030: Conservative, Base and Optimistic Forecast Scenarios (USD Billion)
  • Table 21.26 Oral Proteins / Peptides Market: Market Attractiveness Analysis by Therapeutic Area, 2018 and 2030 (USD Billion)
  • Table 21.27 Oral Proteins / Peptides Market: Distribution by Key Players, 2018, 2024 and 2030 (USD Billion)
  • Table 21.28 Oral Proteins / Peptides Market: Distribution by Technology Platforms, 2018, 2024 and 2030 (USD Billion)
  • Table 21.29 Oral Proteins / Peptides Market: Distribution by Geography, 2018, 2024 and 2030 (USD Billion)
  • Table 21.30 Linzess® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.31 Trulance® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.32 TBRIA™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.33 ALLN-177 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.34 Mycapssa™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.35 NTRA-2112 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.36 Oral Semaglutide Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.37 Larazotide INN-202 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.38 NTRA-9620 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.39 AG013 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.40 IMM-124E Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.41 OPRX-106 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.42 KorsuvaTM Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.43 Oral HDV Insulin Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.44 ORMD-0801 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.45 Oshadi Icp Oral Insulin Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.46 Ovarest® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.47 PTG-100 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.48 SYN-004 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.49 V565 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 21.50 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2017)
  • Table 21.51 Oral Proteins / Peptides Market, 2018, 2024 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 3P Biopharmaceuticals
  • 2. 7-Med Health Ventures
  • 3. Aalto Scientific
  • 4. Abbott Laboratories
  • 5. AbbVie
  • 6. Abeona Therapeutics
  • 7. Abingworth
  • 8. ABL Venture Capital
  • 9. Abzena
  • 10. Access Pharmaceuticals
  • 11. ACES Pharma
  • 12. Acorn Biomedical
  • 13. ActoGeniX
  • 14. Adage Capital Management
  • 15. Adams Capital Management
  • 16. Adams, Harkness & Hill Technology Ventures
  • 17. Adar Biotech
  • 18. Adcock Ingram
  • 19. Aegis Capital
  • 20. Aescap Venture
  • 21. Affilogic
  • 22. Affinity Life Sciences
  • 23. AIMM Therapeutics
  • 24. Ajinomoto Althea
  • 25. Alaven Pharmaceutical
  • 26. Alba Therapeutics
  • 27. Albireo Pharma
  • 28. Alcami
  • 29. Alchemia
  • 30. Aldevron
  • 31. Allena Pharmaceuticals
  • 32. Allergan
  • 33. Alliance Medical Products
  • 34. Almac
  • 35. Almirall
  • 36. Alnara Pharmaceuticals
  • 37. Alta Biopharma Partners
  • 38. Althea Technologies
  • 39. Altus Pharmaceuticals
  • 40. Alza Pharmaceuticals
  • 41. Amarillo Biosciences
  • 42. AmatsiQBiologicals
  • 43. AmbioPharm
  • 44. Amgen
  • 45. Anaheim Clinical Trials
  • 46. Anthera Pharmaceuticals
  • 47. Aphios
  • 48. Apotex
  • 49. Aptalis Pharma
  • 50. Aquestive Therapeutics
  • 51. Aravis Ventures
  • 52. ARCH Venture Partners
  • 53. Arena Pharmaceuticals
  • 54. ArisGen
  • 55. Arisaph Pharmaceuticals
  • 56. Armenian Development Agency
  • 57. Asahi Glass
  • 58. Ascent Biomedical Ventures
  • 59. Assaf Harofeh Medical Center
  • 60. Assembly Biosciences
  • 61. Astellas Pharma
  • 62. AstraZeneca
  • 63. Asymchem Laboratories
  • 64. Atara Technology Ventures
  • 65. Atrix Laboratories
  • 66. Augusta University
  • 67. AURA Biotechnologies
  • 68. AutekBio
  • 69. Avaxia Biologics
  • 70. Avid Bioservices
  • 71. Axcan Pharma
  • 72. AzurRx BioPharma
  • 73. Bachem
  • 74. Baekeland Funds
  • 75. Biomedical Advanced Research and Development Authority
  • 76. Barr Pharmaceuticals
  • 77. Batavia Biosciences
  • 78. Baxter BioPharma Solutions
  • 79. Bayer
  • 80. BCN Peptides
  • 81. Beacon Angels
  • 82. Beijing Friendship Hospital
  • 83. Beijing Tiantan Hospital
  • 84. Beijing Tongren Hospital
  • 85. Bessemer Venture Partners
  • 86. Beta Fund
  • 87. Bharat Serums and Vaccines
  • 88. BIBITEC
  • 89. Bill & Melinda Gates Foundation
  • 90. BIND Therapeutics
  • 91. BINEX
  • 92. Bio Elpida
  • 93. Biocell
  • 94. Biocon
  • 95. BioConnection
  • 96. Biodel
  • 97. Bio Farma
  • 98. Biogen
  • 99. Bio-Kinetic Clinical Applications
  • 100. Biolaxy
  • 101. Biolingus
  • 102. Biological Process Development Facility, University of Nebraska
  • 103. Biomatik
  • 104. Biomay
  • 105. BioPharmaceuticals Australia
  • 106. Biosynergy
  • 107. Bio-Synthesis
  • 108. Biotech Fund Flanders
  • 109. BioTechLogic
  • 110. Biotechnology and Biological Sciences Research Council
  • 111. Biotechpharma
  • 112. BioVectra
  • 113. BioVeda Capital
  • 114. Biovest
  • 115. Biovian
  • 116. Black Beret Life Sciences
  • 117. Boehringer Ingelheim Boehringer
  • 118. Bone Medical
  • 119. Bossa Nova Investmentos
  • 120. Boston Harbor Angels
  • 121. Botanix Pharmaceuticals
  • 122. Broadview Ventures
  • 123. Bumi Medic
  • 124. Buttonwood Financial
  • 125. BZ Bank
  • 126. Cadila Healthcare
  • 127. Calvert Research Institute
  • 128. Canaan Partners
  • 129. Canada Armenia Trading House
  • 130. Capsugel
  • 131. Cara Therapeutics
  • 132. CARBOGEN AMCIS
  • 133. Cardinal Health
  • 134. Carmot Therapeutics
  • 135. Catalent Pharma
  • 136. Cathay Venture
  • 137. Cedars-Sinai Medical Center
  • 138. Cell Culture Company
  • 139. Celltrion
  • 140. Celonic
  • 141. Center for Biocatalysis and Bioprocessing, University of Iowa
  • 142. Century Pharmaceuticals
  • 143. Cerbios-Pharma
  • 144. Changhai Hospital
  • 145. Changzheng Hospital
  • 146. Charles River Laboratories
  • 147. Chattem
  • 148. Chemi Peptides
  • 149. ChemPartner
  • 150. Cherrystone Angels
  • 151. Chiasma Pharma
  • 152. Chinese PLA General Hospital
  • 153. Chong Kun Dang Pharmaceutical
  • 154. Circle33
  • 155. ClinSearch
  • 156. CNF Investments
  • 157. Cobra Biologics
  • 158. Column Group
  • 159. Commercial & External Partnership, Industrial Affairs (CEPiA)
  • 160. Connecticut Innovations
  • 161. Constant Pharmaceuticals
  • 162. Cook Pharmica
  • 163. CordenPharma
  • 164. CoreMed
  • 165. Cosmo Pharmaceuticals
  • 166. Courtagen Life Sciences
  • 167. CPC Scientific Peptide Company
  • 168. CRG
  • 169. Crystal Horizon Investments
  • 170. CureDM
  • 171. Cystic Fibrosis Foundation Therapeutics
  • 172. CytoPharm
  • 173. Cytovance® Biologics
  • 174. D.N.A Biomedical Solutions
  • 175. Dalton Pharma Services
  • 176. Devon Park BioVentures
  • 177. Diabetology
  • 178. Diasome Pharmaceuticals
  • 179. Digestive Care
  • 180. DM Bio
  • 181. Docor International
  • 182. Duke University
  • 183. Edward P. Bass Group
  • 184. EirGenix
  • 185. Eli Lilly
  • 186. Elite Research Institute
  • 187. European Medical Association
  • 188. Embio
  • 189. Emergent BioSolutions
  • 190. Emisphere Technologies
  • 191. Emory University
  • 192. Encap Drug Delivery
  • 193. Encorium Group
  • 194. enGene
  • 195. Engineered BioPharmaceuticals
  • 196. Engineering and Physical Sciences Research Council
  • 197. Entera Bio
  • 198. Enteris BioPharma
  • 199. Enterome Bioscience
  • 200. Entrega
  • 201. Esperante Ventures
  • 202. Eti Karle Clinical
  • 203. EuBiologics
  • 204. EUCODIS Bioscience
  • 205. Eurogentec
  • 206. European Commission
  • 207. European Cystic Fibrosis Society
  • 208. Evonik Industries
  • 209. F2 Capital
  • 210. F3 Ventures
  • 211. Ferrer Internacional
  • 212. Ferring Pharmaceuticals
  • 213. Fidelity Management & Research Company
  • 214. Firebird Global Master Fund
  • 215. First Affiliated Hospital of Harbin Medical University
  • 216. Forbion Capital Partners
  • 217. Foresite Capital
  • 218. Forest Laboratories
  • 219. Frazier Healthcare Partners
  • 220. FUJIFILM Diosynth Biotechnologies
  • 221. Gala Biotech
  • 222. GD Searle
  • 223. GE Healthcare
  • 224. General Hospital of Shenyang Military Region
  • 225. Generex Biotechnology
  • 226. GenIBET Biopharmaceuticals
  • 227. Genta
  • 228. GF Ventures
  • 229. GGV Capital
  • 230. Gila Therapeutics
  • 231. Gimv
  • 232. GlaxoSmithKline
  • 233. Glycotope Biotechnology
  • 234. Golden Seeds
  • 235. Goodwin Biotechnology
  • 236. Google Ventures
  • 237. GP-Pharm
  • 238. Grand River Aseptic Manufacturing
  • 239. Granite State Angels
  • 240. Great Point Partners
  • 241. GTP Technology
  • 242. H.I.G. BioHealth Partners
  • 243. Hadassah Medical Center
  • 244. HALIX
  • 245. Harvard Business School Angels
  • 246. Hayashibara Biochemical Laboratories
  • 247. HBM BioCapital
  • 248. HBM Partners
  • 249. Health Biotech
  • 250. Hefei Tianhui Incubator of Technologies
  • 251. Hemispherx Biopharma
  • 252. Hepasome Pharmaceuticals
  • 253. Heptares Therapeutics
  • 254. Hetero Drugs
  • 255. Hoechst Marion Roussel
  • 256. Hoffman La Roche
  • 257. Hong Kong Institute of Biotechnology
  • 258. Horizons Ventures
  • 259. Hovione
  • 260. iBio
  • 261. IDT Biologika
  • 262. IGY Life Sciences and Technology
  • 263. Immuron
  • 264. InCube Ventures
  • 265. Ingro Finanz
  • 266. Inno Biologics
  • 267. InnoMed Fund
  • 268. Innovate Biopharmaceuticals
  • 269. Institute for Promotion of Innovation by Science and Technology
  • 270. Intas Pharmaceuticals
  • 271. Integrity Bio
  • 272. Intrexon
  • 273. Ippon Capital
  • 274. Ipsen Pharma
  • 275. Ironwood Pharmaceuticals
  • 276. iSelect Fund
  • 277. Ivax Pharmaceuticals
  • 278. Janssen Biotech
  • 279. Jennison Associates
  • 280. JMP Securities Stifel
  • 281. Johnson & Johnson
  • 282. Jordanian Pharmaceutical Manufacturing
  • 283. Joslin Diabetes Center
  • 284. Julphar Gulf Pharmaceutical Industries
  • 285. Juvenile Diabetes Research Foundation (JDRF)
  • 286. Kamat PharmaTech
  • 287. KBI Biopharma
  • 288. Kemwell Biopharma
  • 289. KeyBioscience
  • 290. KPC Pharmaceuticals
  • 291. LAMPIRE Biological Laboratories
  • 292. LaunchPad Venture Group
  • 293. Layered Service Provider (LSP)
  • 294. LFB BIOMANUFACTURING
  • 295. Life Sciences Partners
  • 296. Lilly Ventures
  • 297. LODH Immunology Fund
  • 298. Longevity Biotech
  • 299. Lonza
  • 300. LuinaBio
  • 301. Lumira Capital
  • 302. Lundbeckfonden Ventures
  • 303. Lyfebulb
  • 304. Maine Angels
  • 305. Mallinckrodt Pharmaceuticals
  • 306. Marathon Capital Development Fund
  • 307. Maruishi Pharmaceutical Company
  • 308. Mass Medical Angels
  • 309. Massachusetts Institute of Technology
  • 310. Maverick Capital
  • 311. Maxim Group
  • 312. Mayo Clinic Foundation
  • 313. McDonald Partners
  • 314. Medeva Pharmaceuticals
  • 315. Medicxi Ventures
  • 316. MedImmune
  • 317. Medpace
  • 318. Menarini Biotech
  • 319. Mentor Pharmaceuticals
  • 320. Merck
  • 321. Meridian Life Science
  • 322. Merrion Pharmaceuticals
  • 323. Merro Pharmaceutical
  • 324. MHR Fund Management
  • 325. MicroBiopharm Japan
  • 326. MidaSol Therapeutics
  • 327. Midatech Pharma
  • 328. Millennium Pharmaceuticals
  • 329. Ministry of Industry, Trade and Labor of Israel
  • 330. Mitsubishi International
  • 331. Mitsubishi Tanabe Pharma
  • 332. Molecular and Cellular Therapeutics, University of Minnesota
  • 333. Monash University
  • 334. Montaur Capital Partners
  • 335. Morgan Stanley Investment Management
  • 336. MPM Capital
  • 337. MSD Partners
  • 338. MVM Life Science Partners
  • 339. Mylan
  • 340. NanoMega Medical
  • 341. National Institute of Allergy and Infectious Diseases
  • 342. National Institute of Diabetes and Digestive and Kidney Diseases
  • 343. National Institutes of Health
  • 344. National Institute of Neurological Disorders and Stroke
  • 345. National Multiple Sclerosis Society
  • 346. Neuland Laboratories
  • 347. New Generation Technology
  • 348. New River Management
  • 349. NewVa Capital Partners
  • 350. Niagara University
  • 351. Nitto Avecia Pharma Services
  • 352. Nobex
  • 353. NOD Pharmaceuticals
  • 354. Nordmark Arzneimittel
  • 355. Nordic Biosciences
  • 356. North Country Angels
  • 357. Northwest Pituitary Center, Oregon Health & Science University
  • 358. Nova Laboratories
  • 359. Novartis
  • 360. Novartis Venture Fund
  • 361. Novasep
  • 362. Novetide
  • 363. Novex
  • 364. Novimmune
  • 365. Novo Nordisk
  • 366. Nutrinia
  • 367. OctoPlus
  • 368. Ofer Hi-Tech Group
  • 369. Oklahoma Foundation for Digestive Research
  • 370. Olon
  • 371. Omnia Biologics
  • 372. Oragenics
  • 373. Oramed Pharmaceuticals
  • 374. Orange County Research Center
  • 375. OrbiMed
  • 376. Orexigen Therapeutics
  • 377. Oshadi Drug Administration
  • 378. OsoBio
  • 379. Oxford Finance
  • 380. P&G Pharmaceuticals
  • 381. Pacific Venture Opportunity Fund
  • 382. Panacea Biotec
  • 383. Paperboy Ventures
  • 384. Paragon Bioservices
  • 385. Partner Fund Management
  • 386. Patheon
  • 387. Peking University First Hospital
  • 388. Peking University Peoples Hospital
  • 389. Pendopharm
  • 390. Perceptive Advisors
  • 391. Pfizer
  • 392. Pfizer CentreOne
  • 393. Pharmacia & Upjohn
  • 394. Pharmstandard International
  • 395. Pictet Private Equity Investors
  • 396. Pinemount Investments
  • 397. Ping An Ventures
  • 398. Piramal Pharma Solutions
  • 399. Pituitary Center, Baylor St. Luke's Medical Center
  • 400. PlasmaTech Biopharmaceuticals
  • 401. PLIVA
  • 402. Polymun Scientific
  • 403. PolyPeptide Group
  • 404. Pontifax
  • 405. Praxis Pharmaceutical
  • 406. PREMAS Biotech
  • 407. ProBioGen
  • 408. Productos Biologicos
  • 409. ProJect Pharmaceutics
  • 410. ProMab Biotechnologies
  • 411. Prometheus Laboratories
  • 412. Protagonist Therapeutics
  • 413. Protalix Biotherapeutics
  • 414. Provantage® Biodevelopment Services (Merck Millipore)
  • 415. PureTech Health
  • 416. PvP Biologics
  • 417. PX'Therapeutics
  • 418. PYRAMID Laboratories
  • 419. QIC BioVentures
  • 420. Qilu Hospital of Shandong University
  • 421. QS Pharma
  • 422. Quaker BioVentures
  • 423. Queen's University
  • 424. RA Capital Management
  • 425. Rambam Health Care Campus
  • 426. Rani Therapeutics
  • 427. Rebel Pharmaceuticals
  • 428. Reliance Life Sciences
  • 429. Rentschler Biopharma
  • 430. Rho Ventures
  • 431. Richter-Helm BioLogics
  • 432. Ridgeback Capital
  • 433. Rock Springs Capital
  • 434. Rosetta Capital
  • 435. Ruijin Hospital
  • 436. Saffelberg Investments
  • 437. Sahlgrenska University Hospital
  • 438. Salix Pharmaceuticals
  • 439. Sandoz Pharmaceuticals
  • 440. Sanofi
  • 441. Sanyal Biotechnology
  • 442. Schering-Plough
  • 443. Scientific Health Development Partners
  • 444. Scientific Protein Laboratories
  • 445. SciGen
  • 446. Seachaid Pharmaceuticals
  • 447. Senn Chemicals
  • 448. Shanghai Zhongshan Hospital
  • 449. Sheba Hospital
  • 450. Shionogi
  • 451. Shire
  • 452. Sichuang Provincial People's Hospital
  • 453. Sigma Capital Management
  • 454. Sigmoid Pharma
  • 455. Slater Technology Fund
  • 456. Sofinnova Ventures
  • 457. Square 1 Bank
  • 458. SR One
  • 459. SRZ Properties
  • 460. Stallergenes
  • 461. Starfish Ventures
  • 462. Stealth BioTherapeutics
  • 463. Stevanato Group
  • 464. Sucampo Pharmaceuticals
  • 465. SV Health Investors
  • 466. Swiss Caps
  • 467. Symbiosis Pharmaceutical Services
  • 468. SynCo Bio Partners
  • 469. Synergy Pharmaceuticals
  • 470. Synermore Biologics
  • 471. Syngene
  • 472. Synthetic Biologics
  • 473. Syntex Pharm
  • 474. Takeda Pharmaceutical
  • 475. Takeda Ventures
  • 476. Tamares Capital
  • 477. Tamarix Technologies Group
  • 478. Tapemark
  • 479. Tarix Pharmaceuticals
  • 480. Tarsa Therapeutics
  • 481. Tech Coast Angels
  • 482. Temasek Holdings
  • 483. Teva Pharmaceutical
  • 484. Texas Tech University Health Sciences Center
  • 485. The Column Group
  • 486. The First Affiliated Hospital, Zhongshan University
  • 487. The Halifax Group
  • 488. The Native Antigen Company
  • 489. Thiel Foundation
  • 490. Third Affiliated Hospital of Guangzhou Medical University
  • 491. Therapure Biopharma
  • 492. Thermo Fisher Scientific
  • 493. Third Rock Ventures
  • 494. Third Security
  • 495. Tiziana Life Sciences
  • 496. TNT Pharma
  • 497. TPG Biotech
  • 498. TPG Growth
  • 499. Transgene Biotek
  • 500. TranXenoGen
  • 501. Trenzyme
  • 502. TriHealth
  • 503. TVM Capital
  • 504. UCB Pharma
  • 505. Unigene Laboratories
  • 506. Union Hospital of Tongji Medical College of Huazhong University of Science & Technology
  • 507. United States Food and Drug Administration
  • 508. University of Washington
  • 509. University Hospital of South Manchester
  • 510. University of Alabama Fermentation Facility
  • 511. University of Alberta
  • 512. University of California
  • 513. University of Montreal
  • 514. University of Nebraska
  • 515. University of Southern California
  • 516. University of Texas
  • 517. University of Virginia
  • 518. University of Washington
  • 519. USV
  • 520. Vanderbilt-Ingram Cancer Center
  • 521. Varuma
  • 522. Venrock
  • 523. Ventria Bioscience
  • 524. VentureHealth
  • 525. Vertex Pharmaceuticals
  • 526. Vetter Pharma
  • 527. VHsquared
  • 528. Victory Park Capital
  • 529. Virginia Commonwealth University
  • 530. Virtus Inspire Ventures
  • 531. Vista Biologicals
  • 532. VIVUS
  • 533. vTv Therapeutics
  • 534. WACKER Biotech
  • 535. Waisman Biomanufacturing
  • 536. Watson Laboratories
  • 537. Wellington Management Company
  • 538. West China Hospital
  • 539. White Oak Global Advisors
  • 540. Wingate Institute of Neurogastroenterology
  • 541. WuXi AppTec
  • 542. WuXi Healthcare Ventures
  • 543. Wyeth Pharmaceuticals
  • 544. XBiotech
  • 545. Yissum
  • 546. Zealand Pharma
  • 547. Zosano Pharma
  • 548. Zhongshan Hospital
  • 549. Ziff Asset Management
Back to Top